血管紧张素转换酶抑制剂在神经精神疾病中的应用研究现状

Currents situation of application progress of angiotensin converting enzyme inhibitors in neuropsychiatric diseases

血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitor ACEI)是常用的一线抗高血压药。近年来国内外研究发现ACEI类药物可通过作用于经典ACE/AngⅡ/AT1受体途径、ACE2/Ang-(1-7)/Mas受体途径、缓激肽系统等环节,在神经退行性疾病、认知障碍性疾病、焦虑症、抑郁症、脑卒中等疾病的治疗中可能具有重要的临床价值。本文总结了ACEI在神经精神疾病中的药理作用及临床应用进展,为拓展其临床新用途提供参考。

Angiotensin converting enzyme inhibitor(ACEI) is the first-line drug used commonly in the treatment of hypertension. In recent years, relevant literatures domestic and abroad have found that ACEI drugs may have important clinical value in the treatment of neuropsychiatric diseases by acting on the classic ACE/Ang Ⅱ/AT1 receptor pathway, ACE2/Ang-(1-7)/MAS receptor pathway and bradykinin system, etc. Moreover, ACEI may have potential clinical value in the treatment of neurodegenerative disease, cognitive impairment disease, anxiety disorder, depression and stroke. This paper summarized the pharmacological and clinical research progress of ACEI in neuropsychiatric diseases, providing evidence for expanding its new clinical use.